SRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sensus Healthcare (SRTS) is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below its pivot with a weak short-term trend, no strong proprietary buy signal, and no fresh news catalyst. While analysts remain positive overall, the latest target was cut, and the current setup looks more like a wait-and-see than an immediate long-term entry. Based on the provided data, I would not buy it now.
Current pre-market price is 3.42, slightly above the pivot of 3.346 but still within a weak structure. Momentum is poor: MACD histogram is negative at -0.0231 and contracting, RSI_6 is 32.134, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That indicates the broader trend remains under pressure. Support is at 3.083 and 2.92, while resistance sits at 3.61 and 3.773. The stock trend model suggests only modest short-term upside and very limited longer-term follow-through, which does not support an immediate long-term buy.
["Alliance Global maintains a Buy rating.", "New reimbursement codes for 2026 could support future revenue growth for the SRT platform.", "Options sentiment is strongly bullish based on low put-call ratios.", "The stock is trading near a technical support/pivot zone rather than at a stretched valuation level."]
["Latest analyst action cut the price target to $6.50 from $7.50 after Q1 results came in at the low end of expectations.", "No recent news in the past week to act as an event-driven catalyst.", "Technical trend is bearish with SMA_200 > SMA_20 > SMA_5 and a negative MACD histogram.", "No AI Stock Picker or SwingMax signal is present today.", "No significant hedge fund, insider, or congress trading accumulation is reported.", "Financial snapshot data is unavailable, limiting confirmation of fundamental momentum."]
No usable latest-quarter financial snapshot was provided, so there is no reliable quarter-over-quarter revenue or earnings breakdown to assess. The only fundamental clue is the analyst note that Q1 earnings were at the lower end of expectations, which suggests recent operating performance was not strong enough to support a higher target.
Wall Street sentiment is still positive overall, with Alliance Global keeping a Buy rating. However, the trend in targets has turned less favorable: the firm reduced its price target from $7.50 to $6.50 after Q1 results, which signals some caution on forward estimates. Net takeaway: pros still see upside, but the latest revision shows they are less enthusiastic than before.
